ClinicalTrials HQ

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

Active, not recruiting · NCT04495153 · Registry updated 2025-08-22
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCNeoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmActive, not recruitingPhase 22025-08-22NCT04495153

2 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Candel Therapeutics, Inc.6
NYU Langone Health359

14 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Hunter Holmes McGuire VA Medical CenterRichmondUnited States10
Mayo ClinicRochesterUnited States664
Mayo Clinic HospitalPhoenixUnited States41
NYU Langone HealthNew YorkUnited States403
The Ohio State University Wexner Medical CenterColumbusUnited States102
The University of Texas MD Anderson Cancer CenterHoustonUnited States207
Uconn HealthFarmingtonUnited States26
University of ChicagoChicagoUnited States312
University of Maryland, BaltimoreBaltimoreUnited States32
University of PennsylvaniaPhiladelphiaUnited States507
University of UtahSalt Lake CityUnited States137
Vanderbilt University Medical CenterNashvilleUnited States427
Virginia Commonwealth UniversityRichmondUnited States156
Yale University, Yale Cancer CenterNew HavenUnited States4